Tagged with S

Greece The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic and social impact of the COVID-19 pandemic, but for many biopharma industry leaders they also present an opportunity to tackle…

Global In the largest pharma acquisition in four years, Pfizer has picked up oncology biotech Seagen for USD 43 billion. The deal, which could signal a rebound in M&A activity as big pharma companies look to renew their pipelines in preparation for post-COVID and off-patent losses, bolsters Pfizer’s continuing push into…

Europe The European Medicines Agency (EMA) recently published its annual Human Medicines Highlights report, documenting key figures on its recommendations for the authorisation of new medicines in 2022. The Agency gave 89 positive opinions last year and recommended the authorisation of 41 new active substances. See below for a full list.…

Greece Christian Rodseth, VP and managing director for Janssen’s Greece, Poland, and Romania cluster, outlines the multifaceted strengths of his teams, the part of the Janssen portfolio he is most excited to bring to the region, and the policy measures needed to ensure that Greek healthcare remains sustainable and able to…

Switzerland An extract from PharmaBoardroom’s new country-focused series on market access and health technology assessment (HTA), this piece gives the lowdown on price controls and reference pricing systems in Switzerland. Buy The Pharma Legal Handbook: Market Access & HTA – Switzerland here for £359.   1.1 How does price control at…

Brazil Henrique Tada of ALANAC, the association that brings together Brazil’s domestic pharma companies, comments on the evolution of the Brazilian generics, biosimilars, and value-added medicines markets, local laboratories’ internationalisation efforts, and the policy reforms he hopes that the country’s new administration will roll out.   The pandemic has given us…

India The latest news from the Indian pharma industry, including Dr. Reddy’s purchase of Mayne Pharma’s US portfolio; Sun Pharma’s acquisition of Concert Pharma; Bristol Myers Squibb’s expanded Indian footprint and the Cipla manufacturing site under FDA scrutiny.   Dr. Reddy’s to buy Mayne Pharma’s US business for USD 105 million…

Middle East & Africa The Middle East and Africa (MEA), the fifth-largest regional pharma market in the world, is rapidly becoming a pharmaceutical powerhouse with both global and local firms taking advantage of the region’s population and life expectancy growth as well as greater government funding for healthcare and the progress of universal healthcare…

Germany Germany-based pharma and healthcare services group Fresenius has had its share of challenges. After the group’s dialysis division, Fresenius Medical Care (FMC), was hit with a high rate of COVID-19 deaths among patients using its products and other areas of the business were faced with economic headwinds, the group was…

Global Blue Spoon Consulting’s John G. Singer takes aim at the recent anti-Big Pharma rhetoric around the drug pricing crisis in the US, instead calling for a more holistic view of the situation, acknowledging the role being played by pharmacy benefit managers (PBMs). More importantly, Singer sees a new approach to…

LatAm Axios International has been designing and implementing access to healthcare solutions in collaboration with the pharmaceutical industry and other healthcare players across Latin America (LatAm), Europe, the Middle East, Africa, and Asia for over 25 years. Managing Partner Roshel Jayasundera outlines some of the key access challenges in LatAm today,…

Greece Speaking shortly after the unveiling of a EUR 55 million investment in a new factory in Keratea as part of a wider EUR 155 million spend up to 2025, ELPEN’s Theodore Tryfon outlines the company’s ambitious expansion and diversification plans; his hopes for the future of essential medicine manufacturing in…